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Abstract After the triptans, a calcitonin gene-related
peptide blocker (telcagepant) is the first acute medicine that
has been developed primarily for treatment of acute
migraine. Otherwise, the new drugs have been developed
first for other purposes, like anticonvulsants, antihyper-
tensives and antidepressants used for migraine prophylaxis.
For acute attacks, a new way to administer a traditional
drug like dihydroergotamine is under way, and documen-
tation of efficacy in migraine has been gained for some
commonly used painkillers and anti-inflammatory drugs,
and for some herbal extracts. Based on insights into the
basic pathophysiological mechanisms of the disorder, some
drugs have been developed which seem promising in early
phase II studies (NOS inhibitors and 5HT1F-receptor
agonists). In the future, development and enhancements of
existing medicines must be accompanied by increased
efforts to develop truly new migraine drugs based on
knowledge of the pathophysiology if one wishes to reduce
substantially the great burden migraine poses on patients
and society.
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Introduction
Migraine is the most prevalent and probably also the most
costly of the neurological disorders [1], presumably affect-
ing 11% of the population wordwide [2], but allocation of
resources for treatment [3] and research [4] for migraine and
headache in general is not proportional to the societal
importance of these disorders. In spite of this, the last two to
three decades have seen a large progress in knowledge about
the complex biology of migraine. Although many new drugs
are found by serendipity, some potent new medicines are
now developed de novo for migraine primarily on the basis of
insight into the pathophysiology. This includes both central
and peripheral mechanisms, as well as nerves and vessels.
During migraine attacks, there seems to be a gradual sensi-
tization of neurons on different levels [5], first in the
periphery, around vessels and meninges, and then in the
CNS, most likely in the trigeminal nucleus caudalis (TNC).
Much has been learned by studying the complex innervation
of the cephalic vasculature by three different types of
extrinsic nerves (sympathetic, parasympathetic and sensory
trigeminal) and some important transmitters [most notably
calcitonin gene related peptide (CGRP), and nitric oxide
(NO)] [6]. The cerebral vasculature is influenced by intrinsic
cerebral pathways, stemming from serotoninergic, adrener-
gic, cholinergic, glutaminergic and other brainstem centres
[6]. Positron emission tomography studies have shown that
brainstem structures are activated during migraine attacks
[7], which broadly include the pain—modulating centres in
the periaqueductal grey (PAG) and the nucleus raphe mag-
nus (NRM) [7]. A common hypothesis is that the migraine
pain results from a deficiency of 5-HT in the descending pain
modulating system of the brain [8]. However, the typical
migraine aura cannot be directly explained by brainstem
events, but rather by cortical spreading depression (CSD) [9],
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for which not only potassium ions and/or glutamate may play
central roles, but also other ions and transmitters, including
NO [10]. Migraine is clearly a genetic disorder, but the
precise genetic basis for the most common forms is still
unknown. In some cases of familial hemiplegic migraine,
single locus mutations have been found in genes for either a
brain-specific calcium channel (CACNA1A), an ATP-
dependent sodium pump (ATP1A2) or a voltage-gated
sodium channel (SCNA1) [11]. It is believed that also
common migraine forms are channelopathies, i.e. related to
some functional derangement of ion channels.
The purpose of the present review is to look at the expe-
rience we have with the new drugs introduced in this century,
and to give a glimpse of the exciting new possibilities for
drug treatment that may emerge in the years to come. This
means that the triptans, for which extensive reviews [12] and
meta-analyses [13] have been written earlier, are mostly
omitted, but some old drugs may be included if there has
come new evidence for effect, or novel formulations that
may present a meaningful advance. We have also discussed
at some length drugs which ultimately have proven to be
ineffective but which have become quite extensively used
based on limited evidence.
Anticonvulsants
In the 1990s, it became increasingly evident that valproate
was effective for migraine prophylaxis [14], and after this
many new antiepileptic drugs have been tested for migraine.
A Cochrane report [15] on the use of anticonvulsants in
migraine prophylaxis in adults concluded that this drug class
reduced the frequency of attacks with 1–2 per month, and
more than doubled the chance of having a reduction in attack
frequency of more than 50% compared with placebo. Topi-
ramate and valproate contributed most to the effect. Lamo-
trigine, clonazepam, vigabatrin and acetazolamide were not
significantly different from placebo. A review of anticon-
vulsants for paediatric migraine [16] concluded that none of
the drugs had adequate documentation of effect, and the
paper called for new studies to establish safe and efficient
migraine prophylactic drugs for children and youth. Several
cerebral effects of the aniconvulsants may account for their
effect in migraine, such as increase in the inhibitory trans-
mitter GABA, antagonism of the excitatory transmitter
glutamate, inhibition of sodium channels [17] and effects on
calcium-channels in cortical and PAG neurons [18].
Topiramate (TPM) is probably the best documented
migraine prophylactic drug in both episodic migraine (with
and without aura) and in chronic migraine [19–30]
(Table 1). Efficacy is well documented and placebo-subtracted
reduction in migraine frequency (therapeutic gain) in
most studies is around 20%. Adverse events (e.g. pares-
thesias, dizziness, fatigue, weight loss, memory difficul-
ties and language disturbances) are common, but data
from several controlled trials [31] indicate that TPM is
generally safe for use in adult migraineurs. Although the
exact mechanism of action is not known, TPM has several























Storey [19] MoA ? MA 19 (3) 8 125 36 24 26/10 [68
Silvestrini [20] Chronic migraine 14 (1) 8 50 61 60 71/7 36
Brandes [21] MoA ? MA 120 (58) 18 50 24 4 39/23 [34
122 (57) 100 40 20 49/23 [50
121 (47) 200 41 21 47/23 [49
Diener [22] MoA ? MA 139 (45) 18 100 44 24 37/22 [77
143 (78) 200 28 8 (NS) 35/22 [81
Silberstein [23] MoA ? MA 117 (49) 18 50 24 6 (NS) 36/23 [36
125 (42) 100 39 21 54/23 [47
112 (67) 200 41 23 52/23 [47
Silberstein [24] MoA ? MA 138 (45) 12 161 30 10 40/34 90
Silberstein [25] Chronic migraine 153 (73) 12 86 37 9 NA/NA 83
Diener [142] Chronic migraine 32 (8) 12 100 23 24 22/0 75
Keskinbora [27] MoA ? MA 20 (4) 4 43 90 NA NA/NA 40
Ashtari [28] MoA ? MA 31 (1) 8 50 70 NA NA/NA [23
Millan-Guerrero [29] MoA ? MA 45 (10) 12 100 46 NA 60/NA [47
Dodick [30] MoA ? MA 172 (70) 22 91 41 NA 56/NA 67
MA migraine with aura, MoA migraine without aura
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pharmacological properties that may be relevant for its anti-
migraine effect [32–35], such as blockade of voltage-gated
sodium channels, which limits neuronal hyperexcitablility,
blockade of L-type calcium channels which modulates
neurogenic dural vasodilation and CGRP-induced dilatation,
potentiation of GABA-mediated neurotransmission and
reduction of neuronal firing in the trigeminocervical com-
plex, suppression of glutamatergic transmission through
kainate and AMPA receptors, and inhibition of carbonic
anhydrase and activation of potassium currents. The sum of
these effects on neuronal hyperexcitability may inhibit cor-
tical spreading depression, pain transmission in PAG and
signalling through the trigeminal system [35, 36].
With regard to gabapentin, the evidence is still incon-
clusive [15]. Of three randomised, controlled, double-blind
trials (RCDBT) on migraine, one small study demonstrated a
significant improvement of migraine with 1,200 mg gaba-
pentin [37], with only mild side effects (somnolence, dizzi-
ness, tremor fatigue and ataxia) and no drop-outs. Another
multicenter study of 145 patients, giving up to 2,400 mg for
12 weeks also showed a an effect, and also with tolerable
side effects [38]. However, a third study found no effect of
daily doses of 1,200 or 2,000 mg [39]. According to the
Cochrane report, these studies suggest a beneficial effect, but
since the two most relevant studies had methodological
weaknesses it is concluded that the compound needs further
evaluation. But the evidence at present is so promising that
the drug may be tried in problematic migraine patients [15].
For lamotrigine, there is only one RCDBT from 1997
[40], and this study, with a high drop-out rate and change of
dosing regimen during the study, failed to show superiority
over placebo. Otherwise, the more recent studies are open
[41, 42] or only a case report [43]. Overall, the Cochrane
review concludes that the drug lacks proof of efficacy [15].
Another apparently ineffective drug is oxcarbazepine which
was tried for migraine prophylaxis in a relatively large
RCDBT with doses to at least 1,200mg/day [44]. Zonisa-
mide, mostly used as add-on drug in patients with partial
epilepsia, has only been tried in open studies for migraine
prophylaxis [45–48], one of them in paediatric patients. All
show impressive reduction in attack frequency, and tolera-
bility is very good, although a few patients report dysphoria
and concentration problems [45]. Also levetiracetam has
been tested for migraine prophylaxis only in open studies,
whereof two in children and adolescents [49, 50] and one in
adults [51]. No serious side effects were observed, but some
reported irritability and aggressiveness.
Tonabersat, which has anticonvulsive properties in
experimental animal models, is a blocker of gap junctions,
inhibits CSD [52] and neurogenic inflammation, and redu-
ces NO concentrations during CSD [53]. It seems to have no
contractile effect on isolated vessels or myocardium [54],
but it inhibits trigeminally mediated parasympathetic
reflexes on carotid vasculature [55]. A RCDBT [56] on
glyceryl-trinitrate (GTN)-induced migraine attacks in
migraine patients gave inconclusive results, but the study
had to be terminated due to side effects, possibly from the
interaction of GTN and the study drug. In another RCDBT
of tonabersat 40 mg there were no significant differences in
any effect parameter, although numerically all parameters
favoured the substance over placebo. There were no serious
adverse effects, but nausea, dizziness, and headache
occurred more often in the tonabersat group [57]. In one
recent RCDBT of 39 patients suffering from migraine with
aura (both with and without headache, and including
hemiplegic and basilar migraine), there was a significant
effect of tonabersat 40 mg only on the aura attacks and aura
attacks followed by headache, but not on migraine attacks
without aura or headache in general [58]. If larger studies
confirm this finding, tonabersat may be the first drug with a
selective effect on migraine with aura.
Antihypertensive medication
Beta-blockers have been a mainstay in migraine prevention
in most countries, but few new drugs in this group have
been investigated for migraine during the last decade. One
small RCDBT compared one for migraine established beta-
blocker, metoprolol 142.5 mg, with 5 mg nebivolol, which
is a third-generation beta-blocker with high b-1 selectivity,
high lipid solubility to pass the blood–brain barrier, with
little intrinsic activity and also a vasodilatory effect medi-
ated by stimulation of endothelial NO production [59]. Both
drugs gave a similar reduction of migraine attack frequency,
but nebivolol had significantly fewer side effects [60].
The first RCDBT of a drug influencing the renin-angio-
tensin system (RAS) as migraine prophylactic was published
in 2001, when lisinopril, an angiotensin-converting enzyme
inhibitor (ACEI) [61] was shown to have a beneficial effect
in a cross-over study. In 2003, a similar study demonstrated
effect of candesartan, an angiotensin II, 1a-receptor blocker
(ARB) [62]. Recently, an RCDBT on another ARB (telmi-
sartan) showed effect on level with many other migraine
prophylactics, but the study was inconclusive due to low
power for a parallel group study [63]. The favourable side
effect profile has made particularly candesartan an attractive
alternative which has gained popularity in many countries in
spite of the limited documentation of effect (see, e.g. [64]).
For the ACEIs, coughing as a side effect may limit the use.
Additional proof of efficacy of these classes of drugs in
migraine is by open studies for ACEIs [65–67] and by a study
on migraine among hypertensive patients for candesartan
[68]. Also, there is circumstantial evidence that the effect of
candesartan may be a class effect of the ARBs since a large
pharmacoepidemiologic study showed decreased use of
J Headache Pain (2009) 10:395–406 397
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triptans when patients started using an ACEI or an ARB of
any type [69], and a meta-analysis of RCTs with ARBs used
for other indications showed that headache as a side effect
was lower in the ARB group than in the placebo group,
irrespective of the type of ARB [70]. The mechanism for the
antimigrainous action of these drugs is not known, but it is
most certainly not related to decrease in the blood pressure.
Interestingly, there is an intrinsic RAS of the brain within the
blood brain barrier [71], and in the trigeminal ganglion [72],
which has many effects that may be relevant for migraine.
Antidepressants
Considering the reasonably good evidence for the tricyclic
antidepressant amitriptyline as a migraine prophylactic
[73] it is notable that a Cochrane review concluded that the
selective serotonin reuptake inhibitors (SSRIs) are not
effective in migraine or tension-type headache [74]. There
are, however, some studies that indicate preventive effect
of antidepressants that inhibit reuptake of both serotonin
and nor-adrenalin. A RCDBT on 60 migraine patients with
venlafaxine extended release tablets showed effect of both
75 and 150 mg doses [75]. Adverse events occurred mostly
on the highest dose, and they abated with time. An open-
label retrospective chart review of 65 migraine patients
who used duloxetine showed a modest decrease in
migraine frequency after 2 months, the decrease being
most marked in the subgroup with anxiety [76].
Drugs influencing the dopaminergic system
Nausea, often a disabling migraine symptom, is relieved by
antiemetics like metoclopramide or domperidone which are
dopamine 2 (D2) receptor antagonists. These drugs are
useful not only as antiemetics but they may probably also
have some effect against the migraine [77]. Dopamine
receptor blockers have received relatively little attention as
regular anti-migraine drugs, most likely because of the side
effects, but they may be useful for the particularly severe
attacks seen in patients admitted to hospital for their
migraines, where the first-line medications have failed. A
RCDBT of 40 patients coming to the hospital emergency
room demonstrated effect of i.v. infusion of 5 mg of
haloperidol, most patients being pain free within 1 h [78].
Side effects were common and included motor agitation
and sedation. Another similar study of 68 patients [79]
showed that chlorpromazine 0.1 mg/kg intravenously had
effect after 1 h on headache and associated symptoms, the
side effects being postural hypotension and drowsiness.
Intramuscular droperidol, a dopamine antagonist used for
induction of general anaesthesia, was tested in a RCDBT
for acute migraine attacks in 305 patients [80]. There was
effect with regard to headache relief at 2 h for doses 2.5–
8.25 mg. Asthenia, somnolence, anxiety and acathisia were
side effects related to the study drug.
One drug in this class, olanzapine, an atypical dopamine
blocker with relatively low tendency to induce extrapyra-
midal side effects, has been explored as a potential
migraine prophylactic in a retrospective study of 50
migraine patients who had used the drug, usually 5–10 mg
per day [81]. Patients had a significant decrease in head-
ache days and headache severity, but side effects, weight
gain and somnolence, were bothersome.
CGRP receptor blockers
CGRP is released from trigeminal sensory neurons, and its
significance for migraine was suggested in 1990 when it
was shown to be increased in blood sampled from the
jugular vein during ongoing headache attacks [82]. Some
but not all later studies have confirmed this [83]. A further
indication is that infusion of CGRP can induce attacks in
migraine patients [84]. In addition to being a potent
vasodilatator it has a number of other effects, like release
of histamine from mast cells and increased NO production
in ganglion cells [85]. CGRP receptors are present not only
in vessel walls, but also in the central nervous system
(cerebellum, PAG and TNC).
The proof of concept study for CGRP receptor blockade
in migraine was published in 2004 [86] with olcagepant
which had to be given intravenously. Later studies have
been done with the orally administered telcagepant [87, 88].
CGRP receptor blockers inhibit CGRP- induced vasodila-
tation, but under normal circumstances they seem to have no
effect on cardiovascular parameters, and particularly not on
coronary arteries, and they may therefore be used in
migraine patients with coronary disease. Table 2 shows
some of the data from the RCDBTs comparing telcagepant
with either rizatriptan 10 mg [88] or zolmitriptan 5 mg [87],
and it also gives data on the different triptans from a met-
aanalysis [13]. There is no dose–response relationship for
the doses 300–600 mg, and the response rate is not consis-
tently higher than that of the triptans, but the number of side
effects seems somewhat lower. Since the mode of action
differs fundamentally from that of the triptans, it is hoped
that the drug will be a valuable addition to the armamen-
tarium of acute migraine drugs, and particularly for the large
group of patients who are not satisfied with triptans due to
limited efficacy, side effects or contraindications. Recently,
according to the medical trials, database ClinTrials.gov
(Identifier: NCT00797667) a prophylactic study with tel-
cagepant has been terminated because of two patients with
significant elevations in serum transaminases, signifying
398 J Headache Pain (2009) 10:395–406
123
liver toxicity. The fate of telcagepant is therefore somewhat
uncertain at the moment. Definitely, its greatest potential
seems to be as acute migraine medication, and whereas liver
toxicity is not expected with intermittent use, it is a common
experience with most acute migraine medications that a
small percent of patients will use them almost daily.
Although it is unlikely that telcagepant will be investi-
gated for migraine prevention, there may be other ways to
diminish the effect of CGRP than by receptor blockade.
Currently, substances that reduce the circulating CGRP
levels by acting as CGRP scavengers (antibodies and so
called Spiegelmers) are under development, and these may
in the future offer new possibilities of prophylactic treat-
ment [89].
Somatostatin has been found to inhibit CGRP release, and
the transmitter is also found in TNC and PAG. A somato-
statin-analogue, octreotide, was tried subcutaneously in a
RCDBT for migraine attacks, but with negative results [90].
Nitrogen oxide inhibitors
Intravenous infusions of the NO donor glyceryl trinitrate
(GTN) tends to induce headache in all individuals, but
more often in migraineurs who also get a migraine-like
headache after a first phase with headache of more inde-
terminate nature [91]. Interestingly, NO does not seem to
induce aura among patients with this migraine form, only
the pain. NO is produced by degradation of L-arginin by
NO synthetase (NOS) which exists in three different forms,
endothelial, inducible and neuronal NOS (eNOS, iNOS and
nNOS). Vascular effects of nNOS are mediated through
parasympathetic fibres of the facial nerve to cephalic ves-
sels where it mostly dilates arteries and veins but not
arterioles which regulate tissue perfusion. nNOS and eNOS
may both be involved in sensitisation of peripheral nerves
and also central pain pathways. In view of its potentially
important role in migraine, surprisingly few therapeutic
studies have been performed with NOS-inhibitors. One
small study with an NOS inhibitor given intravenously
showed a response rate of 67% among 15 patients, in
comparison to 14% among 15 patients who received pla-
cebo [92]. The study was blinded, but only 2 placebo
patients were included in the study; the 14 others were
historical placebo controls from another study. 3 of the 15
patients experienced some subjective side effects (pressure
over the nose, tingling at the elbows and cold hands). Mean
arterial pressure increased and heart rate decreased.
Hydroxocobalamin (OH-B12) is an NO scavenger, and
in an open study, this compound given nasally for
3 months reduced the migraine frequency compared to the
baseline period [93].
Selective 5-HT1D and 5HT1F-receptor agonists
Triptans act on 5-HT1B and 5-HT1D-receptors, and some also
on 5-HT1F-receptors. 5-HT1B-receptors mediate vasocon-
striction, whereas the 5-HT1D-receptors are believed to be
involved in neurogenic inflammation of the dura. The
selective 5-HT1D-receptor agonist PNU-142633 has been
shown to block plasma extravasation induced by stimulation
of the trigeminal ganglion in rodents [94]. In a small RCDBT
in migraine patients there was no effect on acute attacks [95].
Table 2 Efficacy and adverse events of telgacepant and triptans
Study Type of drug Pain relief
at 2 h (%)
Pain free







Ho et al. [88]* Telcagepant 300 mg 68.1 45.2 32.0 35.3
Telcagepant 400 mg 48.2 24.3 22.0 36.5
Telcagepant 600 mg 67.5 32.1 39.6 40.8
Telcagepant 10 mg 69.5 33.4 18.4 42.0
Placebo 46.3 14.3 11.0 36.2
Ho et al. [87] Telcagepant 150 mg 49.8 17.2 10.7 31
Telcagepant 300 mg 55.0 26.9 20.2.4 37
Zolmitriptan 5 mg 56.4 31.3 18.2 51
Placebo 27.7 9.6 5.0 32
Meta-analyses 2002 Sumatriptan 100 mg 59 (57–60) 29 (27–30) 13 (8–18)
Almogran 12.5 mg 58
Rizatriptan 10 mg Ca. 70 37
Elitriptan 20 mg Ca. 68 Ca. 40
Zolmitriptan 5 mg [60 42 (36–48)
* Only the highest doses are reported here
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A selective 5-HT1F-receptor- agonist (LY334370) has
been tested in a small RCDBT with three different doses
[96]. The two highest doses were clearly superior to placebo.
Side effects were dizziness, somnolence, asthenia and par-
esthesia. This drug may act by blocking neurogenic inflam-
mation or by blocking nociceptive information in the TNC.
The 5-HT1F-receptor- agonists seem to have no vasocon-
strictor effect in the doses tried for migraine, and they may
thus be safe for patients with vascular disorders [97].
Dihydroergotamine delivered by inhalation
In many countries, use of ergotamines decreased markedly
when triptans were introduced, mainly due to side effects
and safety concerns. However, quite recently the case has
been made for a larger role for dihydroergotamine, due to
its fast onset of action, relative safety and effect in par-
ticularly severe and long-lasting attacks [98]. This semi-
synthetic alkaloid has effects on a both adrenergic (a and
b), dopaminergic and serotoninergic receptors, the latter
including 5-HT1B and 5-HT1D. Possibly, renewed interest
in this compound may be awakened by the introduction of
a new device for delivering the drug by inhalation, per-
mitting uptake through the vast and very thin barrier in the
lungs. This unusual way of delivering migraine drugs has
been shown to be well tolerated, with excellent pharma-
cokinetics on level with intravenous administration [99],
and safe even in patients with asthma [100]. A recent
RCDBT has shown that inhalation of dihydroergotamine
mesylate gave pain relief after 2 h in 72% of patients,
which is higher than most oral or intranasal triptans, and
with few side effects [101], and there was a rapid onset of
action, with significant relief already after 10 min. No
additional effect but more side effects (mainly aftertaste)
was seen for a higher dose of 1 mg.
Glutamate receptor blockers
The excitatory amino acid glutamate is believed to play an
important role in CSD. In a small open study, ketamine, an
antagonist of glutamate receptors of the NMDA subtype,
reproducibly reduced aura symptoms with intranasal
administration of the drug, but there was no effect on the
headache [102]. Another drug (LY293558) is an antagonist
of kainat and AMPA glutamate receptors. In a small
RCDBT comparing the drug both with sumatriptan injec-
tions and placebo, LY293558 given intravenously was
effective with regard to pain and accompanying symptoms
of migraine [103]. The effect was somewhat smaller than
with sumatriptan injections, but side effects were fewer.
Capsaicin receptor blockers
Antagonists against ‘‘capsaicin receptors’’, usually referred
to as transient receptor potential vanilloid subfamily,
member 1 (TRPV1), are currently under investigation for
migraine. This receptor type is sensitive to capsaicin,
which gives the burning taste of chilli peppers, and it is
involved in processes causing thermal hypersensitivity.
The fact that it is expressed in both central and peripheral
trigeminal neurons and seems to be involved in neurogenic
inflammation and sensitization makes it an interesting
target for antimigraine drugs [104]. However, a series of
trials of one TRPV1 antagonist, civamide, as acute
migraine treatment has given disappointing results, and the
trials have been terminated [105].
Drugs influencing the prostanoid system
Drugs for migraine exerting their effect through this system
include acetyl salicylic acid and all the NSAIDs, which are
among the most commonly used drugs for migraine. All
these drugs inhibit cyclo-oxygenase (COX) which cataly-
ses the conversion of arachidonic acid to prostaglandin H2,
a precursor of the prostanoids which are important medi-
ators of inflammatory reactions, but which also mediate a
host of other functions. COX exists in at least two forms,
COX 1 which is a constitutive enzyme found in most cells,
and COX 2 which is an inducible enzyme involved in
inflammatory reactions found in macrophages and other
cells involved in inflammation. The classical NSAIDS
inhibit both COX 1 and COX 2 alike, and the gastroin-
testinal side effects (most notably peptic ulcer) are related
to COX 1 inhibition. The selective COX 2 inhibitors seem
to cause less of these side effects, but this advantage is
offset by increase in cardiovascular risk, probably by
lowering vascular prostacyclin production without altering
platelet thromboxane levels [106].
One large RCDBT [107] has shown effect of two dif-
ferent doses of the COX 2 inhibitor rofecoxib 25 and
50 mg for a single migraine attack. Adverse effects were
generally mild or moderate, but more common with the
highest dose. Another large RCDBT has compared two
doses of valdecoxib (20 and 40 mg) with placebo and
sumatriptan 50 mg doses. This showed that valdecoxib was
better than placebo and similar to sumatriptan, but with
fewer side effects [108]. A small open-label study [109],
comparing the effect of yet another COX 2 inhibitor,
celecoxib 400 mg, with that of a classic NSAID (Naproxen
550 mg) for a single migraine attack, found similar efficacy
for the two drugs, but significantly fewer in the celecoxib
group reported epigastric pain.
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Diclophenac has long been shown to have an effect on
migraine attacks. Recently, a new formulation with higher
water solubility (diclophenac DHEP) has demonstrated
effect over placebo, and in lower doses than diclophenac
potassium [110]. Another study tested diclophenac 100 mg
softgel with or without caffeine 100 mg versus placebo in a
triple cross over study in 46 subjects [111]. Only diclophe-
nac ? caffeine showed superiority over placebo at 60 min.
Prostaglandin E2-receptor blockers are now under
investigation for migraine. The EP4-receptor [112], which
mediates some of the effect of prostaglandin E2 (PGE2), is
present in sensory dorsal root ganglia cells. PGE2, an
inflammatory mediator, is also a neuromodulator that may
alter neuronal excitability and synaptic transmission [113].
The blocker BGC20-1531 can antagonise PGE2-induced
dilatation of cranial arteries, but has no effect on coronary,
pulmonary and renal arteries in vitro [112]. Still, proof of
concept studies are lacking for the blocker. Another
blocker, CJ-023,423, has been shown to reduce thermal and
mechanical hyperalgesia in animal models, and is also
effective in controlling inflammatory pain [114].
Corticosteroids
These drugs are often mentioned for treating status
migrainosus, but the scientific documentation has been
poor [115]. A recent Cochrane review [116] identified
seven randomised, placebo-controlled studies of sufficient
quality, whereof five were published in 2006 or later, on its
use in severe migraine in an emergency department setting
[117]. All used ‘‘standard abortive therapy’’ and then pla-
cebo or dexamethasone intravenously or intramuscularly,
in doses from 10 to 24 mg as an adjunct, with follow-up
varying between 1 and 3 days. Overall, for all studies
(n = 738) the risk of recurrence was significantly reduced
by 26% in those receiving dexamethasone, with side effects
similar to those in the placebo-treated group. As for oral
dexamthasone, the effect of adding dexamethason 8 mg to
acute treatment with phenothiazines was not significant
[118], although the absolute risk reduction was 12% in the
steroid treated group.
Paracetamol
For a highly prevalent disease like migraine most patients
from time to time treat their attacks by over the counter
medication (OTC), and the main information they get
about their medication is from the package label [119]. For
this reason, it is important that adequate documentation on
the effect for migraine exists. One RCDBT of acetamino-
phen (paracetamol) 1,000 mg as attack medication
documented a significant effect over placebo and there was
no difference with regard to side effects [119].
Herbal extracts
As with paracetamol, the fact that many patients treat their
attacks with herbal medicines has been the motivation for
testing the effect of the herbs feverfew (Tanacetum par-
thenium) and butterbur (Petastes hybridus) which have
been widely used in traditional medicine. Feverfew is
known to inhibit prostaglandin production and secretion of
serotonin, and to influence contractility of cephalic vessels.
In a recent RCDBT on the prophylactic effect of an extract
given three times daily for 3 months, it was shown to be
effective with regard to frequency of attacks, with side
effects on level with placebo [120]. Butterbur, which has
anti-inflammatory properties, has been investigated for
prophylaxis in two RCDBTs, and both have suggested a
treatment effect [121, 122] with mild side effects.
Botulinum toxin
Based on the knowledge about episodic migraine patho-
physiology it would seem unlikely that a substance like
botulinim toxin (BTX) which blocks the release of acety-
lcholin in the periphery on muscle cells and sweat glands
should be helpful. In pain states where BTX is effective, it
seems to reduce muscle spasms causing the pain, and there is
good evidence that BTX has no intrinsic antinociceptive
effect in experiments on human volunteers (for review see
[123]). Generally, it may be difficult to determine its effect
on headaches due to the possibility of unblinding because of
the visible effect on the scalp muscles and its high placebo
response [123]. In spite of this, many studies have been
performed in both migraine and other headache conditions.
As can be seen from the overview of the six RCTs [124–129]
of botulinum toxin A in Table 3, the effect on migraine is not
convincing. In general, adverse events in these studies are
few and not serious, mostly ptosis and diplopia in a few
patients [124, 125], and usually with the highest doses. In
2006, it was, based on the negative evidence published till
then, concluded that BTX as prophylactic for episodic
migraine and tension-type headache had come to the end of
the road [130]. A similar opinion was expressed in a more
recent review since none of the six controlled studies in
migraine had shown any significant effect, and three of these
studies were assessed as class I evidence [131]. Also, a recent
report for the American Academy of Neurology has con-
cluded that it is ineffective for episodic migraine [132]. In the
debate following the latter report [133], critics objected that
this view was based on admittedly well-conducted studies
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but these used inadequate doses. In answer to this, the authors
of the report stated that evidence-based reviews necessarily
will be limited to the well-performed trials and cannot reflect
all variations in dosages and injection techniques used
among clinicians. Hence, it is always possible that future
studies with refined techniques and measurements may yield
different results, but up till now there is no good evidence to
support the use of BTX in migraine.
Combination drugs
When triptans were introduced, monotherapy with these
drugs supplanted in many countries the use of earlier
combination pills of ergot, caffeine, tranquillizers or
antiemetics. It was claimed that polypharmacy was partly
responsible for side effects and medication overuse.
However, it is obvious that the complex migraine patho-
physiology offers multiple targets for pharmacological
intervention, and today it is argued that drug combinations
could give additional effects compared to monotherapy.
A large RCDBT of the combination of sumatriptan 50 mg
capsules and naproxen 500 mg tablets against monotherapy
of these same drugs [134] showed that the combination was
superior to monotherapy. This was largely confirmed in two
large RCDBTs, including almost 3,000 migraine patients,
which compared the effect of a combination drug of suma-
triptan 85 mg and naproxen 500 mg in one tablet, with
monotherapy of the same drugs and doses, and with placebo
[135]. An open-label safety study on 565 patients treating
more than 24,000 attacks during a year showed that this
combination drug was well tolerated [136]. Patients had
typical triptan side effects, but few gastrointestinal problems,
and there was only one serious cardiovascular event.
A RCDBT showed superiority of IndoProCaf, a combi-
nation drug given as suppositories containing prochlorpera-
zine (a dopamine D2 receptor antagonist) 4 mg, indomethacin
25 mg and caffeine 75 mg, over sumatriptan 25 mg suppos-
itories [137]. The number of adverse events was low and
similar with the two treatments. Another RCDBT with Indo-
procaf tablets (effervescent and coated) [138], with a lower
prochlorperazine dose (2 mg) than the suppositories, showed
similar results as with sumatriptan 50 mg tablets, with effer-
vescent tablets being superior to coated ones.
One RCDBT compared sumatriptan 50 mg with a com-
bination drug containing acetaminophen 500 mg, acetyl-
salicylic acid 500 mg and caffeine 130 mg in a RCDBT
including 170 patients [139] who were advised to treat their
migraine early. The combination was better than sumatriptan
after both 2 and 4 h.
A RCDBT of tramadol 75 mg in combination with
acetaminophen 650 mg for acute migraine attacks showed
that the combination was superior to placebo for pain from
0.5 to 6 h [140].
As preventive treatment, a small RCDBT tested a com-
bination of magnesium 300 mg with riboflavin 400 mg and
feverfew 100 mg, but the combination did not show superior
effect over placebo. However, since riboflavin changes the
colour of the urine, the placebo had to contain 25 mg ribo-
flavin to obtain proper blinding [141]. In that study, the
placebo effect was particularly high, and it is therefore
possible that the negative result was due to an active effect of
the placebo.
Conclusion
The past decade has seen relatively few new medicines for
migraine, and after the triptans were introduced in the 1990s,
the CGRP blocker is the only drug which may soon be ready
for the market and which is a truly innovative drug developed
primarily for migraine, based on knowledge of the patho-
physiology of the disease. Otherwise, new migraine drugs
are mostly medicines that have been designed for other
diseases, most notably some anticonvulsants (topiramate)
and antihypertensives (ACEIs, ARBS, third generation beta-
blockers). We have also obtained documentation of efficacy
in migraine for some well-known painkillers and anti-
Table 3 Randomized placebo-controlled, double blind trials of botulinum toxin A for migraine prophylaxis
Study N Dose and application Result
Silberstein [124] 122 25 and 75 U, forehead and temples Fixed sites 25 U showed better effect than
placebo, not 75 U group
Evers [125] 60 16U in forehead, 100U in forehead and neck Fixed sites No difference between groups
Elkind [127] 418 25 and 50 U in front and sides of head Fixed sites No difference between groups
Aurora [126] 369 110-260 U ‘‘Follow the pain’’ No difference between groups
Relja [128] 495 75, 150, 225 U in various head and neck muscles Fixed sites No difference between groups
Cady [129] 61 139 U, in various head and neck muscles Fixed sites No significant differences in
headache frequency, but with
regard to headache impact
measure
402 J Headache Pain (2009) 10:395–406
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inflammatory medicines (parecetamol, NSAIDS and COX-2
inhibitors) which many patients use anyway, and the same
goes for some herbal extracts. Likewise, corticosteroids and
some dopamine agonists have proven their usefulness for the
very severe attacks encountered in the hospital emergency
room. We also see a movement towards more polypharmacy
with combinations of well-known drugs. While all these
developments undoubtedly represent progress, it is some-
what disquieting that development of some truly innovative
substances, like NOS inhibitors and 5-HT1F blockers, which
have been very promising in early phase II studies, seem to
have come to a halt. It is natural that low-hanging fruits are
picked first, but in the long run, development and enhance-
ment of existing drugs may be an insufficient strategy if the
goal is to obtain substantial improvements for migraine
patients. It is reasonable to believe that the basic science of
migraine has reached such maturity that more new drugs can
now be developed primarily for migraine. This can only be
achieved by a focussed and concerted research effort by
academia and the pharmaceutical industry. While it is con-
siderably more expensive to manufacture a drug de novo,
new effective medicines for migraine will almost certainly
give payback to the developer, produce large savings for
society and reduced suffering for patients.
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